Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXAMINE-HFC: KER-012 in HFpEF
NCT07202000Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of cibotercept in heart failure with preserved ejection fraction (HFpEF), sponsored by Massachusetts General Hospital. Started Jun 2026; status: recruiting.
02
Drugs
cibotercept
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07202000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202000.